Novogene America Revenue and Competitors

Chaoyang District,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Novogene America's estimated annual revenue is currently $118.9M per year.(i)
  • Novogene America's estimated revenue per employee is $155,000

Employee Data

  • Novogene America has 767 Employees.(i)
  • Novogene America grew their employee count by -8% last year.

Novogene America's People

NameTitleEmail/Phone
1
Account ManagerReveal Email/Phone
2
Inside Sales SpecialistReveal Email/Phone
3
Research Technical Support Scientist IIReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Novogene America?

Novogene, headquartered in Beijing with branches in Hong Kong, the U.S. and U.K., is a leading genomics solution provider with cutting edge bioinformatics expertise and the largest Illumina-based sequencing capacity in China. Committed to quality service and scientific excellence, Novogene has achieved rapid growth and industry recognition by working in partnership with diverse healthcare, educational and research institutions around the globe to realize the unlimited potential of the rapidly evolving world of genomics. The company has completed nearly 10,000 major service projects with over 180 publications in top-ranked journals such as Science and Nature series. Novogene is the first company in China to purchase Illumina's HiSeq X Ten System and is the only Illumina Genome Network partner in China. After achieving tremendous success in China, the company is expanding globally and established Novogene Corporation in the U.S. and Novogene Company Limited in the U.K. in 2014 to better serve global customers. 诺禾致源于2011年3月在北京中关村生命科学园注册成立,专注于开拓前沿分子生物学技术和高性能计算在生命科学研究和人类健康领域的应用,致力于成为全球领先的基因组学产品和服务提供者。企业总办公面积近26000 m2,总部位于北京,在天津和美国设有实验基地,并在香港,美国和英国设有子公司。 诺禾致源目前已建成亚太地区通量规模最大的基因测序中心,每年可完成 40000 人全基因组测序的超高通量。包括20台 HiSeq X、1台 HiSeq 4000、 10台 HiSeq 2500/2000、4台 MiSeq、4台 NextSeq 500 和 5台 Life Ion Proton(DA8600)等最先进的基因测序仪;拥有全球领先的高性能计算平台和数据中心,目前物理核数9256个,计算峰值速度175T flops,总内存43TB,总存储6.4PB,有效地支撑了生命科学研究和医疗健康两大领域对大数据分析和存储的需求。 自成立以来,诺禾致源先后获得国家高新技术企业、北京市科技研究开发机构、北京市专利试点单位及双软企业等多项资质与荣誉,并建设有博士后(青年英才)创新实践基地和北京市工程实验室。诺禾致源在全球范围内与众多学术机构建立了广泛的合作关系,完成多项具有国际先进水平的基因组学研究工作,截止2016年8月,诺禾致源与项目伙伴合作发表SCI文章总计180余篇,累积影响因子大于1000,至今已取得软件著作权100项,自主研发专利43项,累计帮助全球近万名客户完成了超过16,000个项目的基因测序及基因组学研究工作。 作为目前国内基因测序领域的佼佼者,诺禾致源的业务覆盖科技服务、肿瘤基因检测及遗传检测三大领域,为全球研究型大学、科研院所、医院、医药研发企业、农业企业等提供基因测序和生物信息技术支持等服务。肿瘤检测依托完整的分子病理检测平台,面向患者、医院和药企提供精准的实体瘤分子病理检测产品与服务,提供肿瘤用药指导、动态监测、肿瘤遗传易感基因检测等肿瘤精准治疗解决方案。在遗传检测方面诺禾致源已开发一系列基于二代测序技术的检测服务,包括孕前基因检测,新生儿基因筛查,个人基因组等产品,致力于开拓基因组学在人类健康领域的应用,专注于生殖健康和个人基因组领域,并为客户提供专业的遗传咨询服务。

keywords:N/A

N/A

Total Funding

767

Number of Employees

$118.9M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Novogene America News

2022-04-20 - Single-Cell Genome Sequencing Market Size, Outlook and ...

... Inc., DNA Electronics, Tecan Genomics, Inc., Novogene Co., Ltd ... Latin America: Brazil and Rest of Latin America.

2022-04-19 - Global Next Generation Sequencing Kit Market 2022 ...

North America (United States, Canada and Mexico); Europe (Germany, France, United Kingdom ... Geneseeq Technology; Burning Rock Biotech; Novogene; Amoydxmed.

2022-04-17 - Global Exome Sequencing Market 2022 Growth Analysis and ...

Novo Gene. The study concentrates on the most important geographical locations in the industry, such as. North America (United States, Canada...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2567.3M14106-1%N/A